stanozolol abbrev stz sold many brand names androgen anabolic steroid aas medication derived dihydrotestosterone dht used treat hereditary developed american pharmaceutical company winthrop laboratories sterling drug approved us food drug administration human use though longer marketed also used veterinary stanozolol mostly discontinued remains available given mouth humans injection muscle unlike injectable aas stanozolol esterified sold aqueous suspension oral tablet drug high oral bioavailability due alkylation allows hormone survive firstpass liver metabolism stanozolol also sold tablet stanozolol one aas commonly used performanceenhancing drugs banned use sports competition auspices international association athletics federations iaaf many sporting bodies anabolic steroid known diuretic effect additionally stanozolol highly restricted us horse stanozolol used success treat venous insufficiency stimulates blood fibrinolysis evaluated treatment advanced skin changes venous disease lipodermatosclerosis several randomized trials noted improvement area lipodermatosclerosis reduced skin thickness possibly faster ulcer healing rates also studied treat hereditary angioedema osteoporosis skeletal muscle stanozolol used physique performanceenhancing purposes competitive athletes bodybuilders side effects stanozolol include virilization masculinization cardiovascular disease hypertension aas stanozolol agonist androgen receptor ar similarly androgens like testosterone affinity androgen receptor stanozolol substrate already potentiated socalled androgenic tissues like skin hair follicles prostate results greater ratio anabolic androgenic activity compared addition due nature stanozolol nonaromatizable hence propensity producing estrogenic effects gynecomastia fluid stanozolol also possess progestogenic activity presence group metabolism stanozolol sterically hindered resulting orally active although also stanozolol high oral bioavailability due presence alkyl group resistance gastrointestinal liver metabolism results medication low affinity human serum sex hormonebinding globulin shbg testosterone stanozolol metabolized liver ultimately becoming glucuronide sulfate biological halflife reported hours taken mouth hours given intramuscular injection form aqueous said duration action one week via intramuscular stanozolol also known synthetic androstane steroid derivative dht methyl group position pyrazole ring attached ring steroid chemical synthesis stanozolol stanozolol subject extensive hepatic biotransformation variety enzymatic pathways primary metabolites unique stanozolol detectable urine days single mg oral dose methods detection urine specimens usually involve gas chromatographymass spectrometry liquid chromatographymass stanozolol brought market us winthrop tradename winstrol europe winthrops partner bayer name also kefauver harris amendment passed amending federal food drug cosmetic act require drug manufacturers provide proof effectiveness drugs fda implemented drug efficacy study implementation desi program study regulate drugs including stanozolol introduced prior amendment desi program intended classify drugs already market effective ineffective needing fda enlisted national research council national academy sciences evaluate publications relevant drugs desi june fda announced conclusions effectiveness certain aas including stanozolol based nasnrc reports made desi drugs classified probably effective adjunctive therapy treatment senile postmenopausal osteoporosis adjunct pituitary dwarfism specific caveat dwarfism growth hormone available lacking substantial evidence effectiveness several indications specifically fda found lack efficacy stanozolol adjunct promote body tissuebuilding processes reverse tissuedepleting processes conditions malignant diseases chronic nonmalignant diseases debility elderly patients emaciating diseases gastrointestinal disorders resulting alterations normal metabolism use preoperative postoperative periods undernourished patients poorrisk surgical cases due traumatism use infants children adolescents reach adequate weight supportive treatment help restore maintain favorable metabolic balance postsurgical postinfectious convalescent patients value pre operative patients lost tissue disease process associated symptoms anorexia retention utilization calcium surgical applications gastrointestinal disease malnourished adults chronic illness pediatric nutritional problems prostatic carcinoma endocrine fda gave sterling six months stop marketing stanozolol indications evidence efficacy one year submit data two indications found probable august september sterling submitted data data sufficient fda allowed drug continued marketed since unmet need drugs osteoporosis pituitary dwarfism sterling required submit fda removed dwarfism indication label stanozolol since human growth hormone drugs come market mandated label stanozolol steroids say adjunctive therapy senile postmenopausal osteoporosis aas without value primary therapy may value adjunctive therapy equal greater consideration given diet calcium balance physiotherapy good general health promoting measures gave sterling timeline submit data indications wanted sterling submitted data fda intended support effectiveness winstrol postmenopausal osteoporosis aplastic anemia december august respectively fdas endocrinologic metabolic drugs advisory committee considered data submitted osteoporosis two meetings held data aplastic anemia april fda announced data sufficient withdrew marketing authority stanozolol senile postmenopausal osteoporosis raising hemoglobin levels aplastic sterling acquired eastman kodak billion kodak sold drug business sterling sanofi sanofi stanozolol manufactured us searle stopped making drug october even drug production sanofi sold stanozolol business ovation pharmaceuticals along two time drug discontinued considered treatment hereditary march lundbeck purchased lundbeck withdrew stanozolol market us company marketing stanozolol pharmaceutical drug us obtained via compounding pfizer marketed stanozolol veterinary drug pfizer spun veterinary business pfizer transferred authorizations market injectable tablet forms stanozolol veterinary drug used veterinary medicine adjunct management wasting diseases stimulate formation red blood cells arouse appetite promote weight gain evidence uses weak used performanceenhancing drug race horses side effects include weight gain water retention difficulty eliminating nitrogenbased waste products toxic liver especially cats may promote growth tumors contraindicated dogs enlarged stanozolol aas commonly used treat hereditary angioedema attacks several drugs brought market specifically treatment disease first cinryze berinert ecallantide kalbitor icatibant firazyr stanozolol still used longterm reduce frequency severity stanozolol generic name stanozolol english german french japanese inntooltip international nonproprietary name usantooltip united states adopted name usptooltip united states pharmacopeia bantooltip british approved name dcftooltip dénomination commune française jantooltip japanese accepted name stanozololum name latin stanozololo name italian dcittooltip denominazione comune italiana estanozolol name androstanazole androstanazol stanazol stanazolol estanazolol unofficial synonyms also known former developmental code name brand names stanozolol marketed include anaysynth menabol neurabol caps stanabolic veterinary stanazol veterinary stanol stanozolol stanztab stargate veterinary stromba strombaject sungate veterinary tevabolin winstrol winstrol depot winstrolv tradename anabol confused anabiol united states like aas stanozolol classified controlled substance federal regulation included schedule iii controlled substances anabolic steroids act passed part crime control act new york state legislature classifies aas dea schedule iii stanozolol synthetic steroids first banned international olympic committee international association athletics federations methods detect many known cases doping sports stanozolol professional athletes stanozolol especially widely used athletes postsoviet countries banned world antidoping united states antidoping stanozolol investigated treatment number dermatological conditions including urticaria hereditary angioedema raynauds phenomenon cryofibrinogenemia httpsenwikipediaorgwikistanozolol